France André Choulika, Chairman and CEO of Cellectis, discusses how UCART will revolutionize cell therapy as a universal gene-edited solution as opposed to the current therapies on the market which uses a patient’s own re-engineered T-cells. Choulika goes on to share how the company is positioning itself for its anticipated commercialization…
France Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB. My vision is that we should be strong enough to assume a leadership position in any space that we seek to participate in During his two terms at…
Pharma André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution; how unlike many of their competitors, they are a gene editing company at the core and why the idea of…
See our Cookie Privacy Policy Here
